FDA Approves #Lirafugratinib for Previously Treated #FGFR2-Altered #Cholangiocarcinoma: www.pharmacytimes.com/view/fda-app...
@duboisrn.bsky.social
@duboisrn.bsky.socialFDA Approves #Lirafugratinib for Previously Treated #FGFR2-Altered #Cholangiocarcinoma: www.pharmacytimes.com/view/fda-app...
@medchemexpress.bsky.social💊 #FDA Drug Approvals — September 2026
#Lirafugratinib, #Isembyld & #Zanvastro bring new approaches targeting FGFR, myostatin & RNA.
#Sevabertinib, #Camizestrant, #Imlunestrant, #Aqneursa & #Joenja expand therapeutic options across cancer, rare diseases & genetic disorders.
